Insider buying last 90 days
No open-market insider purchases were filed for ENSG in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Ensign closed at $182.10 on 9 November 2026, +0.6% on the day. The price sits between the 50-day ($175.39) and 200-day ($181.76) moving averages, inside a 52-week range of $141.58 to $218.00. The GekkoIndex reads 54.2, in the Neutral zone, up 0.2 points over five sessions. Gekko Fair Value is $165.21, so the price is 10.2% above it.
The next earnings report is due on 3 February 2027, 80 days away. Over the last 8 reports the company beat the earnings estimate 8 times, with an average move of 5.4% across the report. Seasonally, the next 20 trading days from this point averaged -0.2% over the last 5 years, rising in 2 of them.
4 firms rate the stock: 3 buy, 1 hold and 0 sell, with a consensus target of $225.80. A typical daily move is about 3.5%, and a typical 20-day move about 4.7%. On the swing-trade checklist, 1 item reads supportive and 2 read as a headwind (fair value, seasonality).
A plain summary of the figures as of the Nov 9, 2026 close.
Ensign scores 1 supportive, 2 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed2 headwinds
Averages disagree
Close $188.41 sits between the 50-day ($176.51) and 200-day ($182.03) averages, or the averages disagree.
See the chart52.1, Neutral
Reading 52.1 is in the Neutral zone.
See the GekkoIndex15.6% above
Price is 15.6% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 80 days
Next report Feb 3, 2027, 80 days away — outside a typical 20-trading-day hold.
See earnings−0.4% on average
From this point in the calendar, the next 20 trading days averaged −0.4% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Ensign closed at $188.41 on Nov 13, 2026, +4.8% over the past year, inside a 52-week range of $141.58 to $218.00.
Use the left and right arrow keys to read daily values.
Put ENSG on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Ensign works in post-acute healthcare, offering nursing care for people recovering from prolonged illness, managing ongoing health conditions, or needing elder care. It is known for combining medical treatment with everyday support such as housing, meal planning, and recreational activities for residents. Its services extend to rehabilitative therapies including physical, occupational, and speech therapy, as well as senior living facilities and mobile diagnostic offerings like X-rays, ultrasounds, and lab work.
The company runs through two divisions, Skilled Services and Real Estate. The Skilled Services arm covers the clinical and residential care work described above, along with sub-acute care and patient transport to and from homes or long-term facilities. The Real Estate arm involves leasing property. Together these divisions supported a network of 252 healthcare facilities located across thirteen U.S. states, including California, Texas, Arizona, and Washington, as of April 2022.
Ensign was founded in 1999 and is based in San Juan Capistrano, California. Its shares are listed on the NASDAQ under the ticker ENSG.
Ensign’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.1, in the Neutral zone, down 2.8 points over five sessions.
Down 2.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | +0.4% | +2.5% | ||
| Accumulation | 230 | +0.4% | +1.4% | ||
| Neutral (current zone) | 401 | +0.4% | +1.6% | ||
| Distribution | 43 | +0.4% | +1.1% | ||
| Selling | 1 | Too few readings yet | |||
Average ENSG share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Ensign trades 15.6% above Gekko Fair Value of $162.99, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Ensign shares are worth, recalculated every trading day.
$162.99
Gekko Fair Value, Nov 14, 2026
15.6% Overvalued
At the end of Aug 2026 the price was 5.8% above the estimate.
No open-market insider purchases were filed for Ensign, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ENSG in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in ENSG were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Ensign has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds ENSG.
Ensign reports on Feb 3, 2027 (80 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 3, 2027
80 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 27, 2026 | $2.03 est $1.97 | $1.48B est $1.51B | +4.1% |
| Jul 27, 2026 | $1.92 est $1.80 | $1.44B est $1.44B | +5.9% |
| Apr 30, 2026 | $1.85 est $1.82 | $1.39B est $1.40B | −1.4% |
| Feb 4, 2026 | $1.82 est $1.75 | $1.36B est $1.37B | +13.6% |
| Nov 3, 2025 | $1.64 est $1.59 | $1.30B est $1.37B | +2.2% |
| Jul 24, 2025 | $1.59 est $1.55 | $1.23B est $1.22B | +7.8% |
| Apr 29, 2025 | $1.52 est $1.49 | $1.17B est $1.17B | +1.5% |
| Feb 5, 2025 | $1.49 est $1.48 | $1.13B est $1.13B | −6.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Ensign is $225.80, +19.8% from the last close, from 4 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 4 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 29 | UBS | $240 | +27.4% |
| Oct 29 | Oppenheimer | $215 | +14.1% |
| Oct 29 | Stephens | $225 | +19.4% |
| Oct 29 | Truist Financial | $210 | +11.5% |
| Oct 27 | UBS | $230 | +22.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Ensign averaged −0.4% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.0% | 4 of 5 |
| Next 10 trading days | −0.6% | 3 of 5 |
| Next 15 trading days | −1.4% | 1 of 5 |
| Next 20 trading days | −0.4% | 2 of 5 |
| Next 30 trading days | +0.5% | 3 of 5 |
For scale, ENSG’s typical 20-trading-day move in either direction is about 4.7%.
Ensign’s market cap is $10.99B, with a P/E ratio of 27.7 and revenue of $5.67B over the last twelve months.
Coverage of Ensign this week reads negative: 0 positive, 2 neutral and 6 negative headlines.
Ensign’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 8.5% above |
| GHGuardant Health | Accumulation | 16.4% below |
| SOLVSolventum | Neutral | 17.0% below |
| BTSGBrightSpring Health Services | Neutral | 11.0% above |
| EHCEncompass Health | Neutral | 14.7% above |
| DVADaVita | Accumulation | 25.6% below |
A peer links to its own page where one exists.
Ensign’s market cap is $10.99B at the Nov 13, 2026 close of $188.41, with 58.34M shares outstanding. The shares trade on a P/E ratio of 27.7.
The consensus analyst 12-month price target for Ensign is $225.80, +19.8% from the last close. Of the 4 firms that rated the stock in the last 90 days, 3 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Ensign is overvalued: the Nov 13, 2026 close of $188.41 is 15.6% above Gekko Fair Value of $162.99. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Ensign is expected to report on Feb 3, 2027 (80 days away). Analysts expect earnings of $2.16 per share on revenue of $1.60B. Ensign beat the earnings estimate in 8 of its last 8 reports, moving 5.4% on average across the report.
Ensign’s 52-week high is $218.00 and its 52-week low is $141.58; it closed at $188.41 on Nov 13, 2026, +4.8% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (earnings risk), 2 as mixed (trend and gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.